Protocol for Assessment of the Efficiency of CRISPR/Cas RNP Delivery to Different Types of Target Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2021 Nov 9

PMID 34752487

Citations 12

Authors

Marina A Tyumentseva

Aleksandr I Tyumentsev

Vasiliy G Akimkin

Affiliations

Soon will be listed here.

Abstract

Background: Delivery of CRISPR/Cas RNPs to target cells still remains the biggest bottleneck to genome editing. Many efforts are made to develop efficient CRISPR/Cas RNP delivery methods that will not affect viability of target cell dramatically. Popular current methods and protocols of CRISPR/Cas RNP delivery include lipofection and electroporation, transduction by osmocytosis and reversible permeabilization and erythrocyte-based methods.

Methods: In this study we will assess the efficiency and optimize current CRISPR/Cas RNP delivery protocols to target cells. We will conduct our work using molecular cloning, protein expression and purification, cell culture, flow cytometry (immunocytochemistry) and cellular imaging techniques.

Discussion: This will be the first extensive comparative study of popular current methods and protocols of CRISPR/Cas RNP delivery to human cell lines and primary cells. All protocols will be optimized and characterized using the following criteria i) protein delivery and genome editing efficacy; ii) viability of target cells after delivery (post-transduction recovery); iii) scalability of delivery process; iv) cost-effectiveness of the delivery process and v) intellectual property rights. Some methods will be considered 'research-use only', others will be recommended for scaling and application in the development of cell-based therapies.

Citing Articles

Enhancing virus-mediated genome editing for cultivated tomato through low temperature.

Kang G, Ko Y, Lee J Plant Cell Rep. 2025; 44(1):22.

PMID: 39762363 DOI: 10.1007/s00299-024-03392-8.

Generation and characterization of CRISPR-Cas9-mediated XPC gene knockout in human skin cells.

Nasrallah A, Rezvani H, Kobaisi F, Hammoud A, Rambert J, Smits J Sci Rep. 2024; 14(1):30879.

PMID: 39730601 PMC: 11681161. DOI: 10.1038/s41598-024-81675-6.

Targeted Integration of siRNA against Porcine Cytomegalovirus (PCMV) Enhances the Resistance of Porcine Cells to PCMV.

Mao H, Li J, Gao M, Liu X, Zhang H, Zhuang Y Microorganisms. 2024; 12(4).

PMID: 38674781 PMC: 11051760. DOI: 10.3390/microorganisms12040837.

Modulation of Equid Herpesvirus-1 Replication Dynamics Using CRISPR/Cas9-Assisted Genome Editing.

Hassanien R, Thieulent C, Carossino M, Li G, Balasuriya U Viruses. 2024; 16(3).

PMID: 38543774 PMC: 10975850. DOI: 10.3390/v16030409.

An Efficient Expression and Purification Protocol for SpCas9 Nuclease and Evaluation of Different Delivery Methods of Ribonucleoprotein.

Evmenov K, Pustogarov N, Panteleev D, Safin A, Alkalaeva E Int J Mol Sci. 2024; 25(3).

PMID: 38338898 PMC: 10855156. DOI: 10.3390/ijms25031622.

References

Liu J, Gaj T, Wallen M, Barbas 3rd C . Improved cell-penetrating zinc-finger nuclease proteins for precision genome engineering. Mol Ther Nucleic Acids. 2015; 4:e232. PMC: 4354341. DOI: 10.1038/mtna.2015.6. View

Mingozzi F, High K . Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013; 122(1):23-36. PMC: 3701904. DOI: 10.1182/blood-2013-01-306647. View

Yin H, Kanasty R, Eltoukhy A, Vegas A, Dorkin J, Anderson D . Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15(8):541-55. DOI: 10.1038/nrg3763. View

Modarai S, Man D, Bialk P, Rivera-Torres N, Bloh K, Kmiec E . Efficient Delivery and Nuclear Uptake Is Not Sufficient to Detect Gene Editing in CD34+ Cells Directed by a Ribonucleoprotein Complex. Mol Ther Nucleic Acids. 2018; 11:116-129. PMC: 5992347. DOI: 10.1016/j.omtn.2018.01.013. View

Brandao K, Tabel V, Atsma D, Mummery C, Davis R . Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies. Dis Model Mech. 2017; 10(9):1039-1059. PMC: 5611968. DOI: 10.1242/dmm.030320. View

Liu C, Wan T, Wang H, Zhang S, Ping Y, Cheng Y . A boronic acid-rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci Adv. 2019; 5(6):eaaw8922. PMC: 6561739. DOI: 10.1126/sciadv.aaw8922. View

Anders C, Jinek M . In vitro enzymology of Cas9. Methods Enzymol. 2014; 546:1-20. PMC: 5074358. DOI: 10.1016/B978-0-12-801185-0.00001-5. View

Gustafsson O, Radler J, Roudi S, Lehto T, Hallbrink M, Lehto T . Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP. Pharmaceutics. 2021; 13(6). PMC: 8232299. DOI: 10.3390/pharmaceutics13060878. View

Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G . Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019; 25(2):229-233. DOI: 10.1038/s41591-018-0327-9. View

10.

Bhandawat A, Sharma V, Rishi V, Roy J . Biolistic Delivery of Programmable Nuclease (CRISPR/Cas9) in Bread Wheat. Methods Mol Biol. 2020; 2124:309-329. DOI: 10.1007/978-1-0716-0356-7_17. View

11.

Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M . Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases. Biochim Biophys Acta Mol Basis Dis. 2018; 1865(5):920-928. PMC: 6658095. DOI: 10.1016/j.bbadis.2018.08.038. View

12.

ODea S, Annibaldi V, Gallagher L, Mulholland J, Molloy E, Breen C . Vector-free intracellular delivery by reversible permeabilization. PLoS One. 2017; 12(3):e0174779. PMC: 5373627. DOI: 10.1371/journal.pone.0174779. View

13.

Colella P, Ronzitti G, Mingozzi F . Emerging Issues in AAV-Mediated Gene Therapy. Mol Ther Methods Clin Dev. 2018; 8:87-104. PMC: 5758940. DOI: 10.1016/j.omtm.2017.11.007. View

14.

Okada C, Rechsteiner M . Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell. 1982; 29(1):33-41. DOI: 10.1016/0092-8674(82)90087-3. View

15.

Santiago-Fernandez O, Osorio F, Quesada V, Rodriguez F, Basso S, Maeso D . Development of a CRISPR/Cas9-based therapy for Hutchinson-Gilford progeria syndrome. Nat Med. 2019; 25(3):423-426. PMC: 6546610. DOI: 10.1038/s41591-018-0338-6. View

16.

Li L, Hu S, Chen X . Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities. Biomaterials. 2018; 171:207-218. PMC: 5944364. DOI: 10.1016/j.biomaterials.2018.04.031. View

17.

Seki A, Rutz S . Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018; 215(3):985-997. PMC: 5839763. DOI: 10.1084/jem.20171626. View

18.

Chen Y, Aslanoglou S, Murayama T, Gervinskas G, FitzGerald L, Sriram S . Silicon-Nanotube-Mediated Intracellular Delivery Enables Ex Vivo Gene Editing. Adv Mater. 2020; 32(24):e2000036. DOI: 10.1002/adma.202000036. View

19.

Sharma P, Cho H, Lee J, Ham W, Park B, Cho N . Efficient intracellular delivery of biomacromolecules employing clusters of zinc oxide nanowires. Nanoscale. 2017; 9(40):15371-15378. DOI: 10.1039/c7nr05219g. View

20.

Gaj T, Guo J, Kato Y, Sirk S, Barbas 3rd C . Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods. 2012; 9(8):805-7. PMC: 3424280. DOI: 10.1038/nmeth.2030. View